Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512863 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6509444 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6510310 | 0.79 | IDO1 (0.45) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6518055 | 0.79 | IDO1 (0.45) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL17230505 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6512047 | 0.78 | IDO1 (0.46) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6511578 | 0.76 | TAAR1 (0.47) | ALDH1A1SMN1; SMN2PKMMAPTIDO1 | |
| SCHEMBL673608 | 0.73 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL10499968 | 0.73 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2GAAHTTIDO1 | |
| SCHEMBL7997853 | 0.71 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2GAAPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | ROSENTHAL SANDRA J (US) | 2005-09-01 | — | — | US | disclosed |
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-10 | — | — | US | disclosed |
| WO-2001090716-A2 | LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF | VANDERBILT UNIVERSITY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129590-A1 | Linker arms for nanocrystals and compounds thereof | SCO2, NCL, NCAPH | ALDH1A1 2277/4885SMN1; SMN2 1359/4885GAA 3530/4885 |
| US-20050192430-A1 | Linker arms for nanocrystals and compounds thereof | NCL, CHN2, SCO2 | ALDH1A1 3030/4885SMN1; SMN2 1903/4885GAA 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.